Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DEQW79
|
|||
| Drug Name |
LY3532226
|
|||
| Indication | Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 1 | [1] | |
| Company |
Lilly Indianapolis, IN
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastric inhibitory polypeptide receptor (GIPR) | Target Info | Agonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | G alpha (s) signalling events | |||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05407961) A Phase 1b, 2-Part, Investigator- and Participant-Blind, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3532226 in Participants With Type 2 Diabetes Mellitus. U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.